Market
How will major media outlets perceive McKinsey's role in the opioid crisis by 2025?
2
Resolution / Starting Odds
Significantly negative • 25%
Moderately negative • 25%
Neutral • 25%
Positive • 25%
Analysis of major media outlets or public opinion surveys
Story
McKinsey to Pay $650 Million in Opioid Settlement Over 'Turbocharging' Purdue Pharma Sales
Dec 13, 2024, 04:20 PM
McKinsey & Company has agreed to pay $650 million to settle a US Department of Justice investigation into its role in advising opioid manufacturers, including Purdue Pharma, on strategies to boost sales of opioid painkillers such as OxyContin. The settlement, which includes a five-year deferred prosecution agreement, allows McKinsey to avoid a guilty plea while resolving criminal and civil investigations into the consulting firm's work that prosecutors say contributed to the opioid epidemic, which has claimed hundreds of thousands of lives in the United States. As part of the agreement, a former McKinsey partner will plead guilty to obstruction of justice for destroying documents related to the firm's efforts to 'turbocharge' opioid sales. McKinsey accepted responsibility for its actions, including conspiring with Purdue Pharma and others to aid and abet the misbranding of prescription drugs.
View original story
Similar markets
More Negative • 25%
Unchanged • 25%
More Positive • 25%
Remains the Same • 25%
No • 50%
Yes • 50%
Federal Trade Commission • 25%
Securities and Exchange Commission • 25%
Other • 25%
U.S. Department of Justice • 25%
McKinsey & Company • 25%
Bain & Company • 25%
Boston Consulting Group • 25%
Other • 25%
Deloitte • 25%
Other • 25%
Accenture • 25%
McKinsey & Company • 25%
Increase • 25%
Uncertain/Other • 25%
No significant change • 25%
Decrease • 25%
$1.5 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $1 billion • 25%
$1 billion to $1.5 billion • 25%
